KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Moderna (MRNA) Non Operating Income (2018 - 2026)

Moderna (MRNA) has disclosed Non Operating Income for 9 consecutive years, with -$18.0 million as the latest value for Q1 2026.

  • For Q1 2026, Non Operating Income fell 350.0% year-over-year to -$18.0 million; the TTM value through Mar 2026 reached -$22.0 million, up 69.44%, while the annual FY2025 figure was -$8.0 million, 90.8% up from the prior year.
  • Non Operating Income hit -$18.0 million in Q1 2026 for Moderna, down from -$12.0 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $14.0 million in Q2 2023 and bottomed at -$51.0 million in Q3 2023.
  • Average Non Operating Income over 5 years is -$17.6 million, with a median of -$13.0 million recorded in 2022.
  • On a YoY basis, Non Operating Income climbed as much as 207.69% in 2023 and fell as far as 628.57% in 2023.
  • Moderna's Non Operating Income stood at -$12.0 million in 2022, then plummeted by 225.0% to -$39.0 million in 2023, then grew by 25.64% to -$29.0 million in 2024, then soared by 58.62% to -$12.0 million in 2025, then crashed by 50.0% to -$18.0 million in 2026.
  • According to Business Quant data, Non Operating Income over the past three periods came in at -$18.0 million, -$12.0 million, and $8.0 million for Q1 2026, Q4 2025, and Q2 2025 respectively.